RedHill Biopharma (RDHL) Total Current Liabilities (2014 - 2025)

RedHill Biopharma (RDHL) has 12 years of Total Current Liabilities data on file, last reported at $19.2 million in Q4 2025.

• On a quarterly basis, Total Current Liabilities fell 13.51% year-over-year to $19.2 million in Q4 2025; TTM through Dec 2025 was $19.2 million, a 13.51% decrease from a year earlier, with the FY2025 full-year figure at $19.2 million, down 13.51% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $19.2 million, down from $22.3 million in the prior quarter.
• Over the last five years, Total Current Liabilities for RDHL reached as high as $197.5 million in Q4 2022 and fell as low as $19.2 million in Q4 2025.
• Historically, Total Current Liabilities has averaged $65.8 million across 5 years, with a median of $25.2 million in 2023.
• Across the five-year window, Total Current Liabilities jumped 142.36% in 2022 and slumped 89.88% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $81.5 million in 2021, then soared by 142.36% to $197.5 million in 2022, then slumped by 89.88% to $20.0 million in 2023, then grew by 11.21% to $22.2 million in 2024, then retreated by 13.51% to $19.2 million in 2025.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $19.2 million in Q4 2025, $22.3 million in Q2 2025, and $22.2 million in Q4 2024.